BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 915 filers reported holding BAXTER INTL INC in Q4 2013. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $4,917,000 | -61.8% | 149,688 | -18.7% | 0.06% | -57.9% |
| Q2 2015 | $12,873,000 | +1.9% | 184,080 | -0.2% | 0.13% | +6.4% |
| Q1 2015 | $12,638,000 | +99.9% | 184,502 | +113.9% | 0.12% | +56.2% |
| Q4 2014 | $6,322,000 | -36.6% | 86,255 | -37.9% | 0.08% | -15.8% |
| Q3 2014 | $9,968,000 | +7.8% | 138,895 | +8.6% | 0.10% | +11.8% |
| Q2 2014 | $9,250,000 | +4.7% | 127,940 | +6.5% | 0.08% | -1.2% |
| Q1 2014 | $8,837,000 | +33.7% | 120,100 | +26.3% | 0.09% | +32.3% |
| Q4 2013 | $6,611,000 | +15.8% | 95,060 | +9.3% | 0.06% | +3.2% |
| Q3 2013 | $5,711,000 | – | 86,940 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |